Pathos · 18 hours ago
Senior Computational Biologist, Oncology
New York, NY
Full-time
Hybrid
Senior Level
$150K/yr - $170K/yrPathos is building a next-generation biotech with AI at the core, aiming to redefine drug development in oncology. The Senior Computational Biologist will be responsible for designing and maintaining genomics pipelines, generating biomarker hypotheses, and collaborating with clinical teams to optimize drug development strategies.
Artificial Intelligence (AI)BiotechnologyLife ScienceMedicalTherapeutics
Responsibilities
Design, build, and maintain end-to-end translational genomics pipelines supporting oncology drug programs, including RNA-seq, DNA (SNV/CNV/structural variants), and multi-omic integration
Generate and prioritize genomically grounded hypotheses tailored to different therapeutic modalities, including:
Target dependency and pathway activation for small molecules Expression, heterogeneity, and spatial context for mAbs, bispecifics, and ADCs Biomarkers of payload sensitivity, internalization, and resistance for ADC programs
Lead biomarker discovery and validation efforts across preclinical, translational, and clinical datasets, with a focus on:
Predictive and pharmacodynamic biomarkers
MOA and pathway activity signatures
Resistance and escape mechanisms
Analyze and interpret clinical trial biomarker data (Phase 1/2), linking molecular profiles to response, durability, safety, and survival endpoints
Partner closely with clinical, translational, and regulatory teams to:
Define biomarker strategies for trial protocols
Support dose escalation/expansion decisions
Inform indication prioritization and patient enrichment strategies
Translate multimodal model outputs and large-scale genomic analyses into clear, defensible recommendations for development teams and leadership
Contribute to cross-program biomarker standards, best practices, and reproducible analysis frameworks across the Pathos portfolio
Qualification
Required
PhD (or equivalent industry experience) in computational biology, cancer genomics, bioinformatics, or a related field
Direct experience supporting oncology drug development in a translational, biomarker, or early clinical (Phase 1/2) setting
Deep expertise in cancer genomics and transcriptomics, including hands-on experience with RNA-seq and DNA variant analysis in clinical contexts
Strong understanding of translational biomarkers across the drug development lifecycle, from hypothesis generation to clinical readouts
Experience analyzing biomarker data from interventional clinical trials, including response modeling, survival analysis, and subgroup discovery
Experience generating and validating genomic and multi-omic hypotheses across multiple drug modalities, including small molecules, monoclonal antibodies, bispecifics, and ADCs, with an understanding of how mechanism of action shapes biomarker strategy
Strong intuition for modality-specific biomarker requirements, such as target expression thresholds, pathway addiction, synthetic lethality, immune context, and resistance biology
Demonstrated ability to integrate genomic data with clinical endpoints and operational trial data
Familiarity with large oncology datasets (e.g., Tempus, TCGA, AACR GENIE) and applying them to inform development strategy
Fluency in R (and/or Python) with a strong emphasis on reproducibility and scientific rigor
Thinks like a drug developer, not just a data scientist—understands what makes a biomarker actionable in a real clinical program
Comfortable owning analyses that influence high-stakes decisions, including trial design and program prioritization
Excels at cross-functional collaboration with clinicians, translational scientists, and engineers
Able to clearly communicate complex genomic and biomarker findings to both technical and non-technical stakeholders
Company
Pathos
Pathos is a biotechnology company that leverages AI to accelerate oncology drug development.
Founded in 2020
11-50 employees
H1B Sponsorship
Pathos has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (1)
2023 (1)
Funding
Current Stage
Late StageTotal Funding
$447MKey Investors
New Enterprise Associates
2025-05-15Series D· $365M
2024-10-29Series C· $62M
2023-03-02Series Unknown· $20M
Leadership Team
Ryan Fukushima
Co-Founder
Recent News
2025-10-27
2025-09-19
Company data provided by crunchbase